Duragesicfentanyl

According to the FDA label: Fentanyl transdermal system is indicated for the management of severe and persistent pain in opioid-tolerant patients, that requires an opioid analgesic and that cannot be adequately treated with alternative options, including immediate-release opioids.

96,508 adverse event reports submitted to the FDA (1997–2026)

This data reflects voluntary reports submitted to the FDA's Adverse Event Monitoring System (AEMS), formerly the FDA Adverse Event Reporting System (FAERS). A report does not mean the medication caused the event. Data may be incomplete or contain errors. Learn more about AEMS. New to this data? Read our guide on how to interpret FDA adverse event reports →
New to FDA adverse event data? Here's how to read these reports →

Top Reported Adverse Events

The most frequently reported events in association with Duragesic in the FAERS database. These are events reported by patients taking this medication, not necessarily caused by it. A single report may include multiple events.

Show these terms with plain-language definitions

Tap any term below for a plain-language definition.

Browse the full glossary →

Ranked by frequency of reports, not severity. The most-reported event is not necessarily the most dangerous or the most common in patients taking this drug.

Who Is Reporting

Demographics of patients in FAERS reports that included this information. Not all reports include patient demographics.

By Sex

View reporter sex data as a table
Duragesic adverse event reports by reporter sex
SexReports
Female44,941
Male43,001
Unknown421

By Age Group

View age group data as a table
Duragesic adverse event reports by reporter age group
Age groupReports
0-173,768
18-3412,063
35-4913,462
50-6417,821
65-7410,776
75+8,189

This shows who filed reports, reflecting who takes this drug and who tends to report, not who is at greatest risk.

Reported Outcomes

Outcomes recorded in FAERS reports that included Duragesic. A single report may involve multiple reactions, each with a different outcome. These categories are defined by FDA reporting guidelines, not by PillSignal.

View outcome data as a table
Duragesic adverse event reports by reported outcome
OutcomeReports
Other Serious51,424
Hospitalization32,530
Death27,463
Non-Serious14,432
Life-Threatening8,249
Disability3,052

Serious outcomes are far more likely to be reported than mild ones, so this overstates how often outcomes are serious. A recorded death does not mean the drug caused it.

Number of FAERS reports received per quarter for Duragesic. Changes in volume may reflect shifts in prescribing rates, media attention, or reporting behavior, not changes in the medication's safety profile.

View report trend as a table
Duragesic adverse event reports by year
YearReports
19971
19983
20011
20041,119
20051,460
20061,161
20071,042
20081,030
20091,096
20101,987
20113,202
20122,778
20133,378
20143,383
20154,869
20165,150
20176,316
20187,151
20196,897
20208,374
20217,806
20228,333
20236,562
20246,084
20256,196
2026 (partial)1,129

The steep increase around 2004 reflects the FDA's move to electronic submission, not a change in this drug's safety. Trends track reporting volume, not risk.

Medications commonly reported with Duragesic

In FDA adverse event reports that mention Duragesic, these medications appeared most often in the same report.

This reflects co-occurrence in submitted reports, not evidence of drug interaction or combined risk. People often report several medications taken for the same condition or for unrelated reasons. Talk to a doctor or pharmacist about your specific medications.

Other medications with similar adverse event profiles in FDA FAERS reports.

Data Source

This data is sourced from the FDA's Adverse Event Monitoring System (AEMS), formerly FAERS, via the OpenFDA API. PillSignal is not affiliated with the FDA.

View this data on the FDA website →

Data last updated: June 2026